Group Health Research Institute, Seattle, Washington 98101, USA.
J Am Geriatr Soc. 2011 Oct;59(10):1899-907. doi: 10.1111/j.1532-5415.2011.03586.x. Epub 2011 Sep 13.
To examine whether use of opioids or benzodiazepines is associated with risk of community-acquired pneumonia in older adults.
Population-based case-control study.
An integrated healthcare delivery system.
Community-dwelling, immunocompetent adults aged 65 to 94 from 2000 to 2003. Presumptive pneumonia cases were identified from health plan automated data and validated through medical record review. Two controls were selected for each case with pneumonia, matched on age, sex, and calendar year.
Information about opioid and benzodiazepine use came from computerized pharmacy data. Information on covariates including comorbid illnesses and functional and cognitive status came from medical record review and electronic health data.
One thousand thirty-nine validated cases of pneumonia and 2,022 matched controls were identified. One hundred forty-four (13.9%) cases and 161 (8.0%) controls used prescription opioids (adjusted odds ratio (OR) = 1.38, 95% confidence interval (CI) = 1.08-1.76 vs nonuse). Risk was highest for opioids categorized as immunosuppressive based on immunological studies (OR = 1.88, 95% CI = 1.26-1.79 vs nonuse), whereas for nonimmunosuppressive opioids the OR was 1.23 (95% CI = 0.89-1.69). Risk was highest in the first 14 days of use (OR = 3.24, 95% CI = 1.64-6.39 vs nonuse). For long-acting opioids, the OR was 3.43 (95% CI = 1.44-8.21) versus nonuse, whereas for short-acting opioids, it was 1.27 (95% CI = 0.98-1.64). No greater risk was seen for current benzodiazepine use compared to nonuse (OR = 1.08, 95% CI = 0.80-1.47).
Use of opioids but not benzodiazepines was associated with pneumonia risk. The differences in risk seen for different opioid regimens warrant further study.
探讨老年人群中使用阿片类药物或苯二氮䓬类药物是否与社区获得性肺炎的风险相关。
基于人群的病例对照研究。
一个综合医疗服务系统。
2000 年至 2003 年期间,居住在社区、免疫功能正常的 65 至 94 岁成年人。从健康计划自动数据中确定疑似肺炎病例,并通过病历回顾进行验证。每个肺炎病例匹配 2 个对照,按年龄、性别和日历年份匹配。
阿片类药物和苯二氮䓬类药物使用信息来自计算机化的药房数据。包括合并症以及功能和认知状态在内的协变量信息来自病历回顾和电子健康数据。
共确定了 1039 例经验证的肺炎病例和 2022 例匹配对照。144 例(13.9%)病例和 161 例(8.0%)对照使用了处方阿片类药物(调整后的优势比(OR)=1.38,95%置信区间(CI)=1.08-1.76 与未使用相比)。基于免疫学研究,将阿片类药物归类为免疫抑制的风险最高(OR=1.88,95%CI=1.26-1.79 与未使用相比),而非免疫抑制性阿片类药物的 OR 为 1.23(95%CI=0.89-1.69)。在使用的前 14 天内风险最高(OR=3.24,95%CI=1.64-6.39 与未使用相比)。对于长效阿片类药物,OR 为 3.43(95%CI=1.44-8.21)与未使用相比,而对于短效阿片类药物,OR 为 1.27(95%CI=0.98-1.64)。与未使用相比,当前使用苯二氮䓬类药物与肺炎风险无关(OR=1.08,95%CI=0.80-1.47)。
使用阿片类药物而非苯二氮䓬类药物与肺炎风险相关。不同阿片类药物方案的风险差异值得进一步研究。